Stand Up To Cancer’s signature “Dream Teams” pursue translational cancer research projects that address critical challenges in cancer prevention, diagnosis, and treatment to deliver near-term patient benefit through investigation by a multi-disciplinary, multi-institutional, collaborative team of expert investigators and patient advocates. These teams, selected and guided by leaders in the field, take innovative ideas from concept to laboratory to patient, testing ideas that have the potential to revolutionize cancer care and open whole new fields of investigation.
Projects may focus on particular organ sites, molecular pathways of cancer, patient populations, or innovative approaches to research. They are designed to accelerate the application of new preventive, diagnostic, or therapeutic approaches in the clinic that lead to patient involvement within the first two to three years of the grant funding period.
Dream Team members span many disciplines and utilize the new tools of modern biology to attack research questions in a coordinated way with a focus on measurable milestones of progress. SU2C employs a variety of mechanisms to foster collaborations within and among the Dream Teams and to promote the sharing of information. The large, competitive Dream Team grants typically provide between $6 million and $22 million per team over three or four years and are accompanied by rigorous scientific oversight to provide additional insight and to ensure compliance with grant proposals and established benchmarks.
In 2009, SU2C launched five Dream Teams as its first projects. Since then, a total of 24 Dream Teams have been selected. Many of these are co-branded with one or more nonprofit collaborators, and two of the teams are branded more specifically as Cancer Interception Teams because of their focus on using emerging discoveries for the earliest possible treatment of cancer.
For information about SU2C’s research, including Dream Teams, visit StandUpToCancer.org/research.